Loading
TGFBR3 (Transforming growth factor beta receptor type 3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis. Initiates BMP, inhibin, and TGF-beta signalling pathways by interacting with different ligands including TGFB1, BMP2, BMP5, BMP7 or GDF5. Alternatively, acts as a cell surface coreceptor for BMP ligands, serving to enhance ligand binding by differentially regulating BMPR1A/ALK3 and BMPR1B/ALK6 receptor trafficking.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · TGFBR3 (Transforming growth factor beta receptor type 3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
TGFBR3 (Transforming growth factor beta receptor type 3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis.
No product in this corpus aims at TGFBR3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA TGFBR3: RNA low tissue specificity; blood lineage group enriched (NK-cells 17 nTPM, T-cells 35 nTPM); high antibody staining in 2 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas TGFBR3 tissue; Open Targets ENSG00000069702 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Moren et al, Biochem. Biophys. Res. Commun, 1992, "Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors". Source.
Sources: HGNC HGNC:11774 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q03167 (protein name, function text, keywords and locations (REST API)); CIViC gene TGFBR3 (1 evidence items, 0 assertions, 1 variants; diseases: Prostate Cancer (GraphQL API, CC0))
Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis. Initiates BMP, inhibin, and TGF-beta signalling pathways by interacting with different ligands including TGFB1, BMP2, BMP5, BMP7 or GDF5. Alternatively, acts as a cell surface coreceptor for BMP ligands, serving to enhance ligand binding by differentially regulating BMPR1A/ALK3 and BMPR1B/ALK6 receptor trafficking. Promotes epithelial cell adhesion, focal adhesion formation and integrin signalling during epithelial cell spreading on fibronectin. By interacting with the scaffolding protein beta-arrestin2/ARRB2, regulates migration or actin cytoskeleton and promotes the activation of CDC42 as well as the inhibition of NF-kappa-B. In gonadotrope cells, acts as an inhibin A coreceptor and regulates follicle-stimulating hormone (FSH) levels and female fertility. Location: Cell membrane; Secreted; Secreted, extracellular space, extracellular matrix (UniProt). Locus 1p22.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: group enriched (NK-cells 17 nTPM, T-cells 35 nTPM).
Medium: Adrenal gland, Breast, Caudate, Cerebral cortex, Gallbladder, Hippocampus, Kidney, Lung.
No cancer stained high; medium in renal cancer, urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TGFBR3" OR ABSTRACT:"TGFBR3" OR TITLE:"transforming growth factor beta receptor 3" OR ABSTRACT:"transforming growth factor beta receptor 3" OR TITLE:"Transforming growth factor beta receptor type 3" OR ABSTRACT:"Transforming growth factor beta receptor type 3" OR TITLE:"betaglycan" OR ABSTRACT:"betaglycan" OR TITLE:"BGCAN" OR ABSTRACT:"BGCAN") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TGFBR3, not a curated reading list.